289 results about "B cell" patented technology

The embodiment of the invention provides an end-to-end B cell clone pedigree forest construction method and related equipment, and can be applied to the technical field of data processing. According to the method, a plurality of obtained receptor sequencing sequences are subjected to germline comparison identification to obtain a first test Fv sequence corresponding to each receptor sequencing sequence, and a germline Fv sequence corresponding to each receptor sequencing sequence is generated; performing integrity filtering on the first test Fv sequence, performing clone type division to obtain a plurality of first clone type sets, constructing corresponding first evolutionary trees to form a first pedigree forest on the basis of a second clone type set contract type conversion probability, and performing node optimization on all the first evolutionary trees to obtain a second pedigree forest; and after it is determined that the homotype category conversion probability after updating based on all the second evolutionary trees meets the preset requirement, visualization processing is performed on all the second evolutionary trees, so that the systematic cognition efficiency of related personnel on the adaptive immune response mechanism can be improved.

This invention discloses a monoclonal antibody against human hepatitis B e antigen and its application, relating to the field of hepatitis B detection technology. In the heavy chain variable region of the monoclonal antibody, the amino acid sequences of the complementarity-determining regions (CDR1-3) are as shown in SEQ ID NO. 1-3 or have at least 95% homology with the sequences shown in SEQ ID NO. 1-3; in the light chain variable region, the amino acid sequences of the complementarity-determining regions (CDR1 and CDR3) are as shown in SEQ ID NO. 4 and 5 or have at least 95% homology with the sequences shown in SEQ ID NO. 4 and 5, and the amino acid sequence of the complementarity-determining region (CDR2) is FAS. The monoclonal antibody provided by this invention can effectively recognize natural hepatitis B e antigen, and the titer of the supernatant from B cell culture can reach 1:10000, making it fully applicable to the detection and research of human hepatitis B e antigen. The chemiluminescent reagent prepared using the monoclonal antibody described in this invention has advantages such as high specificity, strong anti-interference ability, high detection sensitivity, and good stability, with almost no missed detections, and can replace imported reagents.

The invention provides application of a substance for detecting the ratio of lymphocyte subgroups in preparation of a reagent or a kit for diagnosis or auxiliary diagnosis of Graves disease, and belongs to the technical field of preparation of disease diagnosis reagents. A research shows that compared with a healthy sample, the proportion of B cells in a lymphocyte subpopulation of a to-be-detected sample is remarkably increased, the proportion of NK cells is remarkably reduced, the proportion of activated T cells is remarkably reduced, the proportion of memory T cells is remarkably reduced, the proportion of CD4 + memory T cells is remarkably reduced, the proportion of Th1 cells is remarkably reduced, and the proportion of Tc1 cells is remarkably reduced, so that the to-be-detected sample is a GD patient; the substance for detecting the ratio of lymphocyte subgroups is high in sensitivity and specificity when being used for diagnosis or auxiliary diagnosis of Graves disease.

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

A method for determining if an agent is suitable for treating a Rheumatoid Arthritis (RA) patient, the method comprising determining the profile of a first, second and / or third marker panel in a sample from the patient, wherein the agent is selected from an agent that downregulates TNF mediated signalling, an agent that downregulates IL-6 mediated signalling and a B cell targeted therapy.

The application discloses a tandem antigen epitope peptide of G protein of Paralichthys olivaceus rhabdovirus and application thereof, and belongs to the field of fish molecular immunology. The amino acid sequence of the tandem antigen epitope peptide is shown as SEQ ID NO:1. The preparation method of the application comprises the following steps: (1) first, analyzing the structural characteristics of HIRRV-G protein and predicting B cell antigen epitopes, and synthesizing the antigen epitopes with advantages based on the prediction results; (2) then, screening candidate peptide segments with high affinity through enzyme-linked immunosorbent assay; (3) sequentially connecting the high-affinity peptide segment sequences meeting the requirements by using a GPGPG linker, and cloning the connected sequences into a pET-28a prokaryotic expression vector, so that the tandem antigen epitope peptide is obtained after induced expression. Compared with the full-length G protein, the tandem antigen epitope peptide has smaller molecular weight, stronger stability and stronger hydrophilicity; the tandem antigen epitope peptide can induce a large amount of specific antibodies in fish bodies, and significantly reduces the mortality of fish infected by the virus. The tandem antigen epitope peptide can be used for the development of HIRRV diagnostic reagents and subunit vaccines.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.

Described herein is a method of treating, ameliorating, and / or preventing an influenza viral infection in a subject, and / or immunizing a subject against an influenza viral infection, which include parenterally administering to the subject a first composition including a first compound in an amount sufficient to elicit systemic T and / or B cell response(s) against a first influenza virus in the subject; and administering to the subject a second composition including a viral protein of a second influenza virus through an administration route comprising intranasal, inhalational, intratracheal, intrapulmonary, and intrabronchial, in an amount sufficient to result in establishment of tissue-resident T cell(s), tissue-resident B cell(s), mucosal IgA, and / or systemic IgG specific against the influenza viral infection in the subject. Also described are a kit for performing the method, as well as methods and kits for boosting existing immunity against influenza viral infections.

The application discloses a B cell immune repertoire antibody sequence feature analysis and specific screening method and related equipment, which can be applied to the technical field of data processing. According to the application, after the antibody sequencing sequence is subjected to germ line comparison and recognition to obtain corresponding first sequencing Fv sequence and germ line Fv sequence, the first sequencing Fv sequence is subjected to gene integrity filtering and structure integrity filtering, clonotype division and root node sequence reconstruction to obtain a second clonotype collection, and then a first lineage forest is constructed, and according to the second sequencing Fv sequence, the second clonotype collection or the first lineage forest, sequence feature analysis in multiple dimensions is carried out, so that the antibody sequence features can be analyzed from multiple dimensions such as sequence quality, sequence abundance, mutation degree, mutation preference and aggregation degree, the filtered BCR sequence has high affinity, and according to the sequence feature analysis results in multiple dimensions or the first lineage forest, a visualized graph is generated, so that relevant personnel can view the sequence features.

Disclosed are methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells. The methods may relate to stage-specific differentiation from stem cells or stem-cell derived hematopoietic progenitors through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells.

This invention provides a recombinant conjugate protein against EBV virus and its application. The recombinant conjugate protein is a conjugate of recombinant protein HBc-SC and recombinant EBV antigen protein. In the recombinant conjugate protein, the molar ratio of recombinant protein HBc-SC to recombinant EBV antigen protein is 1:1 to 1:12. The amino acid sequence of the recombinant protein HBc-SC is shown in SEQ ID NO:1. The recombinant EBV antigen protein includes a recombinant gHgL fragment and a tag sequence. The recombinant gHgL fragment is shown in SEQ ID NO:3. The tag sequence is shown in SEQ ID NO:5, and the tag sequence is located at the C-terminus of the recombinant EBV antigen protein. The recombinant conjugate protein provided by this invention can induce strong humoral immunity, significantly increasing neutralizing antibody titers in epithelial cells and B cells, making it an excellent candidate vaccine for preventing EBV virus infection.

The patent discloses an antibody against human IgG, a preparation method and application thereof, a heavy chain variable region of the antibody comprises heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and amino acid sequences are respectively shown as SEQ ID NO:1-3; a light chain variable region comprises light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, and amino acid sequences are respectively shown as SEQ ID NO:4-6. The application efficiently prepares a high-activity monoclonal antibody which can combine with different subtypes of human IgG Fc by using an in-vitro culture method of B cells, and specifically relates to two monoclonal antibodies which can specifically combine with human IgG1 protein, and provides a powerful tool for detecting human IgG1 protein and researching diseases related to human IgG1 protein.

The invention relates to the technical field of biological medicine, and discloses an anti-human 5T4 single-chain antibody, the antibody has the capability of specifically binding to human 5T4 protein, the human 5T4 protein corresponds to TPBG / WAIF1, and the GenBank login number is NP001018111.1; the antibody also has the capability of specifically binding and expressing human 5T4 protein tumor cells, and the human 5T4 protein tumor cells are breast cancer cells MCF-7, prostate cancer cells PC3 or gastric cancer cells MGC-803. By combining single B cell culture with a magnetic bead sorting technology, natural pairing of a heavy chain and a light chain of an antibody can be reserved, and the defect that pairing is damaged by a traditional hybridoma technology is overcome; meanwhile, false positive clones are effectively eliminated through double positive screening of detecting protein binding activity through ELISA and detecting cell binding activity through FACS, the finally obtained targeting 5T4 monoclonal antibody can be specifically combined with human 5T4 protein and tumor cells expressing the protein, and a high-quality targeting molecular basis is provided for research and development of subsequent antibody drugs and CAR-T cell treatment products.

The invention discloses a kit and a method for preparing cDNA (complementary deoxyribonucleic acid) by reverse recording of a single B cell of a mouse. The kit comprises a B cell lysis solution and a reverse transcription buffer solution system, wherein the B cell lysis solution is prepared from a nonionic detergent, dNTP (deoxyribonucleoside triphosphate), dCTP (deoxycytidine triphosphate), a secondary structure stabilizer, a reducing agent, BioIS-mCH2-RT (reverse transcriptase), BioIS-CK-RT, a mouse RNA (Ribonucleic Acid) enzyme inhibitor and nuclease-free water; the reverse transcription buffer solution system comprises 5X RT Buffer, a secondary structure stabilizer, Mg < 2 + >, a reducing agent, a mouse RNA enzyme inhibitor, a Bio-Adaptor primer, reverse transcriptase and nuclease-free water. The kit can significantly improve the success rate, accuracy and sensitivity of reverse transcription of a single B cell, and simplify the operation process.

The invention discloses a yellow fever virus envelope protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. Yellow fever virus envelope protein E expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the yellow fever virus envelope protein E are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the monoclonal antibody with high neutralizing activity and capable of completely protecting mice from yellow fever virus lethal attack is obtained by using the monoclonal antibody as a template, connecting the monoclonal antibody and the constant region gene to an expression vector, carrying out mammalian cell expression and purification, and carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse virus attack experiment, such that the monoclonal antibody has high neutralizing activity and can completely protect mice from yellow fever virus lethal attack; the monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention relates to an immune system humanized mouse biological system for preparing a fully humanized monoclonal antibody and a method for preparing the fully humanized monoclonal antibody. The method comprises the following steps: using a constructed immune system humanized mouse and a VLP chimeric antigen; the HSC immune system humanized mouse is an immunodeficient mouse transplanted with human immune cells, the human immune cells are reconstructed, and antigen-specific B cells and fully humanized antibodies can be generated in the immune system humanized mouse by using a VLP chimeric antigen without firstly activating DC and antigen-specific T cells. In addition, by coupling a VLP antigen and a target antigen, a specific B cell and a fully human antibody of any target can be generated.

The present invention relates to methods for efficiently generating recombinant monoclonal antibodies derived from B cells of a non-human host which has been immunochallenged with one or more target antigens. The methods comprise the steps of identifying and isolating B cell that bind to the antigen by FACS, and recombining and enriching for thousands of cells to create a B cell library. Related products and methods, such as methods of producing expression libraries, are also disclosed.

Provided herein are immuno-responsive cells expressing a B cell targeting pCAR comprising a 2nd generation chimeric antigen receptor (CAR) and a chimeric co-stimulatory receptor (CCR). Also provided herein are methods of preparing the immuno-responsive cells and methods of directing T cell mediated immune response using the immuno-responsive cells.

Human immunoglobulin light chain transgene constructs are provided that encode at least two different rearranged light chain V-J regions arranged in such a manner that only one of the alternate light chains is expressed from the construct upon recombination in B cells. In some embodiments, the transgene comprises two, three or four different rearranged light chain V-J regions. Transgenic animals comprising the transgene are also provided. The light chain transgenes thus allow for expression of two, three or four alternate fixed light chains in the animals. Methods of using the transgenic animals are also provided.

The invention provides a B cell or CD11b + cell targeted nano-liposome and application thereof, and the B cell or CD11b + cell targeted nano-liposome is prepared from polyethylene glycol and derivatives thereof, cholesterol, phosphate fat and derivatives thereof which are self-assembled in different proportions and selectively act on B cells or CD11b + cells in a targeted manner under the condition that bioactive molecules are not coupled. And various anti-cancer new dosage forms, vaccine dosage forms and gene therapy vectors are prepared based on the nano-liposome capable of targeting B cells or CD11b + cells.

The invention provides a fusion protein vaccine and application thereof. Specifically, the invention provides a fusion protein and a pharmaceutical composition of the fusion protein and an STING agonist, and provides application of the pharmaceutical composition. According to the fusion protein vaccine disclosed by the invention, the titers of a specific neutralizing antibody and a binding antibody are remarkably improved, the broad spectrum and durability are enhanced, and the immune response of T cells is remarkably improved; besides, the fusion protein vaccine promotes the generation of memory T and B cells, effectively improves immune memory induced by the vaccine, provides a new strategy for preventing and / or treating diseases induced by respiratory tract infection, and has a wide application prospect.

To provide an improved treatment strategy for multiple sclerosis (MS) patients, especially for long-term treatment. In particular, B-cell depleting MS therapies are provided without unnecessarily affecting serum levels of immunoglobulins.SOLUTION: A B-cell and / or T-cell inhibitor for use in the treatment of multiple sclerosis, wherein said treatment comprises: (a) optionally administering a B-cell and / or T-cell inhibitor other than ofatumumab; (b) monitoring serum IgG levels; (c) selecting ofatumumab as a B-cell and / or T-cell inhibitor if the serum IgG level decreases. A B-cell and / or T-cell inhibitor for use.SELECTED DRAWING: None

The invention belongs to the technical field of biology, and discloses an anti-human CD38 antibody and application thereof. The anti-human CD38 antibody disclosed by the invention can be specifically combined with human CD38 protein, and the combination is stable. The antibody is coupled with an adsorption column to pertinently adsorb B cells in blood, so that the level of pathogenic factors can be quickly reduced, and abnormally activated or pathogenic B cells in circulation and pathogenic factors such as antibodies, cell factors and the like generated by the abnormally activated or pathogenic B cells are quickly reduced, thereby quickly relieving symptoms. The B cells can be cleared relatively specifically, and the influence on other cells is reduced. The traditional Chinese medicine composition has the advantages that time is bought for other treatments, in the acute attack or serious stage of diseases, illness state stabilization is facilitated, favorable conditions are created for subsequent immunoregulation treatment or other targeted treatment, immune imbalance can be improved, the imbalance state of an immune system can be adjusted, and immune homeostasis can be recovered. When necessary, adsorption can be repeatedly carried out to maintain the treatment effect, and the safety is high.

The application discloses a porcine rotavirus VP7 protein conserved dominant B cell antigen epitope peptide or a combination thereof or a nucleic acid molecule and application, and further discloses a porcine rotavirus VP7 protein polyepitope fusion protein and a preparation method and application thereof.The polyepitope fusion protein can not only induce high-level specific antibody response and cellular immune response to the VP7 protein, effectively inhibit porcine rotavirus infection, but also has high safety and stability.Compared with a traditional fusion protein, the polyepitope fusion protein has significant advantages in production cost and immunization efficacy, and provides a feasible porcine rotavirus prevention and control scheme for the pig industry.

The invention discloses polymer nanoparticles for colorectal cancer immunotherapy as well as a preparation method and application of the polymer nanoparticles. Small interfering RNAsiDhx9 is entrapped in the nanoparticles, a CD19 antibody is coupled to the surfaces of the nanoparticles, and immunotherapy of colorectal cancer is realized by specifically silencing Dhx9 on B cells. The nanoparticles provided by the invention not only can activate cytotoxic T (CD8 + T) cells, induce powerful anti-tumor immune response and remarkably inhibit the progress of colorectal cancer, but also can enhance the immune memory effect.

The present invention belongs to the technical field of medicine, and specifically relates to the use of a compound as represented by the following formula (I) or a pharmaceutically acceptable salt, isomer, or crystal form thereof in the preparation of a drug for preventing or treating malignant B cell tumors.